Preclinical models showed augmented infiltration of CD4+ and PD-1+/CD8+ T cells and reduced tumor-associated macrophages secreting IL-1β and CCL18 when VEGFR inhibition was introduced [276,277]. This evidence concerns the gene KDR and neoplasm.